Refractory Epstein-Barr Virus (EBV)-related post-transplant lymphoproliferative disease
- Post-transplant lymphoproliferative disease (PTLD) represents a serious complication following allogeneic hematopoietic stem cell transplantation (alloHSCT). Previously, survival rates of PTLD have improved due to the introduction of rituximab. However, reports on curative management of refractory PTLD are scarce. Today, there is no consensus how to treat rituximab-refractory PTLD, especially in highly aggressive disease. Here, we describe successful management of refractory EBV-associated PTLD, specifically DLBCL, with combined brentuximab vedotin and third-party EBV-specific T-cells in a multidisciplinary treatment approach.
| Author: | Thomas MikaORCiDGND, Katharina StrateGND, Swetlana Ladigan-BaduraORCiDGND, Clemens AignerGND, Uwe SchlegelGND, Iris TischoffGND, Sabine Tischer-ZimmermannGND, Britta Eiz-VesperGND, Britta Maecker-KolhoffGND, Roland SchroersORCiDGND |
|---|---|
| URN: | urn:nbn:de:hbz:294-77480 |
| DOI: | https://doi.org/10.3389/fmed.2019.00295 |
| Parent Title (English): | Frontiers in medicine |
| Subtitle (English): | cure by combined brentuximab vedotin and allogeneic EBV-specific T-lymphocytes |
| Publisher: | Frontiers Media |
| Place of publication: | Lausanne |
| Document Type: | Article |
| Language: | English |
| Date of Publication (online): | 2021/01/08 |
| Date of first Publication: | 2019/12/18 |
| Publishing Institution: | Ruhr-Universität Bochum, Universitätsbibliothek |
| Tag: | Open Access Fonds PTLD; aggressive lymphoma; alloHSCT; brentuximab vedotin (BV); third party EBV-specific t-lymphocytes |
| Volume: | 6 |
| Issue: | Artikel 295 |
| First Page: | 295-1 |
| Last Page: | 295-5 |
| Note: | Article Processing Charge funded by the Deutsche Forschungsgemeinschaft (DFG) and the Open Access Publication Fund of Ruhr-Universität Bochum. |
| Dewey Decimal Classification: | Technik, Medizin, angewandte Wissenschaften / Medizin, Gesundheit |
| open_access (DINI-Set): | open_access |
| Licence (English): |  Creative Commons - CC BY 4.0 - Attribution 4.0 International |
